Resources from the same session
5704 - Safety and Efficacy of TRIplet combination of Nivolumab (N) with Dabrafenib (D) and Trametinib (T) [TRIDeNT] in Patients (pts) with BRAF-mutated Metastatic Melanoma (MM): A Single Center Phase II Study
Presenter: Elizabeth Burton
Session: Poster Discussion – Melanoma and other skin tumours
Resources:
Abstract
4298 - 3-year relapse-free survival (RFS), overall survival (OS) and long-term toxicity of (neo)adjuvant ipilimumab (IPI) + nivolumab (NIVO) in macroscopic stage III melanoma (OpACIN trial)
Presenter: Christian Blank
Session: Poster Discussion – Melanoma and other skin tumours
Resources:
Abstract
4560 - Cell Phenotypes Associated with Response and Toxicity Defined by High Resolution Flow Cytometry in Melanoma Patients receiving Checkpoint Inhibition
Presenter: Jeffrey Weber
Session: Poster Discussion – Melanoma and other skin tumours
Resources:
Abstract
4008 - Unsorted single-cell RNA sequencing profiles of metastatic melanoma patients reveal the heterogeneity of melanoma-associated fibroblasts
Presenter: Krisztian Homicsko
Session: Poster Discussion – Melanoma and other skin tumours
Resources:
Abstract
4800 - Plasma proteomics in patients with metastatic cutaneous melanoma treated with immune checkpoint inhibitors
Presenter: Hanna Eriksson
Session: Poster Discussion – Melanoma and other skin tumours
Resources:
Abstract
1090 - Talimogene laherparepvec (T-VEC) in combination (combo) with ipilimumab (ipi) versus ipi alone for advanced melanoma: 3-year landmark analysis of a randomized, open-label, phase 2 trial
Presenter: Jason Chesney
Session: Poster Discussion – Melanoma and other skin tumours
Resources:
Abstract
1989 - Phase II multicenter open label study of pembrolizumab and entinostat in adult patients with metastatic uveal melanoma (PEMDAC study)
Presenter: Henrik Jespersen
Session: Poster Discussion – Melanoma and other skin tumours
Resources:
Abstract
3622 - Pembrolizumab for Recurrent/Metastatic Cutaneous Squamous Cell Carcinoma (cSCC): Efficacy and Safety Results From the Phase 2 KEYNOTE-629 Study
Presenter: Jean Jacques Grob
Session: Poster Discussion – Melanoma and other skin tumours
Resources:
Abstract
3904 - SELPAC - a 3 arm randomised Phase II study of the MEK inhibitor selumetinib alone or in combination with paclitaxel (PT) in metastatic uveal melanoma (UM)
Presenter: Paul Nathan
Session: Poster Discussion – Melanoma and other skin tumours
Resources:
Abstract
7194 - Phase II Study of Neoadjuvant Cemiplimab Prior to Surgery in Patients with Stage III/IV (M0) Cutaneous Squamous Cell Carcinoma of the Head and Neck (CSCC-HN)
Presenter: Neil Gross
Session: Poster Discussion – Melanoma and other skin tumours
Resources:
Abstract